Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

Fig. 2

Changes in total adiponectin during tocilizumab treatment. Patients received IV tocilizumab monthly for 12 months with or without csDMARDs. They were evaluated at month M0, M1, M3, M6 and M12. The number of patients at each visit is indicated. Results are shown as mean ± SEM (paired Student’s t test: ***p = 0.0022 at month 1; *p = 0.0105 at month 3)

Back to article page
\